CD8A and neoplasm: Furthermore, silencing LINC01132 can induce CD8+ T cell infiltration, and when combined with anti-PD-L1 treatment, can improve anti-tumor immunity, suggesting that LINC01132 may serve as a novel immunotherapeutic target in HCC.